AffiliationClinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK. email@example.com
MetadataShow full item record
AbstractOver recent years the role of biomarkers in anticancer drug development has expanded across a spectrum of applications ranging from research tool during early discovery to surrogate endpoint in the clinic. However, in Europe when biomarker measurements are performed on samples collected from subjects entered into clinical trials of new investigational agents, laboratories conducting these analyses become subject to the Clinical Trials Regulations. While these regulations are not specific in their requirements of research laboratories, quality assurance and in particular assay validation are essential. This review, therefore, focuses on a discussion of current thinking in biomarker assay validation. Five categories define the majority of biomarker assays from 'absolute quantitation' to 'categorical'. Validation must therefore take account of both the position of the biomarker in the spectrum towards clinical end point and the level of quantitation inherent in the methodology. Biomarker assay validation should be performed ideally in stages on 'a fit for purpose' basis avoiding unnecessarily dogmatic adherence to rigid guidelines but with careful monitoring of progress at the end of each stage. These principles are illustrated with two specific examples: (a) absolute quantitation of protein biomarkers by mass spectrometry and (b) the M30 and M65 ELISA assays as surrogate end points of cell death.
CitationBiomarker method validation in anticancer drug development. 2008, 153 (4):646-56 Br. J. Pharmacol.
JournalBritish Journal of Pharmacology
- Fit-for-purpose biomarker method validation in anticancer drug development.
- Authors: Cummings J, Ward TH, Dive C
- Issue date: 2010 Oct
- Validation of analytic methods for biomarkers used in drug development.
- Authors: Chau CH, Rixe O, McLeod H, Figg WD
- Issue date: 2008 Oct 1
- Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.
- Authors: Cummings J, Zhou C, Dive C
- Issue date: 2011 Apr 15
- Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
- Authors: Valentin MA, Ma S, Zhao A, Legay F, Avrameas A
- Issue date: 2011 Jul 15
- A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
- Authors: Altar CA, Amakye D, Bounos D, Bloom J, Clack G, Dean R, Devanarayan V, Fu D, Furlong S, Hinman L, Girman C, Lathia C, Lesko L, Madani S, Mayne J, Meyer J, Raunig D, Sager P, Williams SA, Wong P, Zerba K
- Issue date: 2008 Feb